Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Outset Medical, Inc. (OM)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $119.5M | $113.7M | $130.4M | $115.4M | $102.6M | $49.9M | $15.1M | $2.0M |
| Gross profit | $46.8M | $38.6M | $29.0M | $17.8M | $7.6M | −$13.0M | −$17.8M | −$6.1M |
| Research & development | $21.2M | $38.4M | $57.3M | $48.9M | $36.7M | $28.9M | $23.3M | $22.9M |
| Operating expenses | $113.5M | $151.9M | $198.8M | $178.9M | $138.1M | $104.4M | $52.5M | $40.4M |
| Operating income | −$66.7M | −$113.4M | −$169.8M | −$161.0M | −$130.5M | −$117.5M | −$70.3M | −$46.6M |
| EBITDAderived | −$62.4M | −$107.6M | −$164.0M | −$155.8M | −$125.4M | −$114.3M | −$68.8M | −$45.5M |
| Net income | −$81.7M | −$128.0M | −$172.8M | −$163.0M | −$131.9M | −$121.5M | −$68.3M | −$49.8M |
| Basic EPSper diluted share | -$5.37 | -$36.96 | -$52.28 | -$3.38 | -$2.89 | -$4.85 | -$99.58 | -$100.75 |
| Diluted EPSper diluted share | -$5.37 | -$36.96 | -$52.28 | -$3.38 | -$2.89 | -$4.85 | -$99.58 | -$100.75 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 3, 2026Form 4 | Gaeta ReneeChief Financial Officer | SellCommon Stock | 17.7K | $4.94 | $87.3K | 113.8K |
| May 15, 2026Form 4 | Trigg LeslieChair and CEO | SellCommon Stock | 3.4K | $3.70 | $12.7K | 98.9K |
| May 15, 2026Form 4 | Nash MarcEVP Operations R&D & Service | SellCommon Stock | 1.6K | $3.70 | $5.9K | 38.4K |
| May 15, 2026Form 4 | Brottem John L.General Counsel | SellCommon Stock | 2.6K | $3.70 | $9.8K | 30.3K |
| Feb 17, 2026Form 4 | Nash MarcEVP Operations R&D & Service | SellCommon Stock | 1.8K | $3.35 | $6.1K | 40.0K |